PMGC Holdings Subsidiary Grants Exclusive License to Modulant Biosciences

Reuters
Feb 11
<a href="https://laohu8.com/S/ELAB">PMGC Holdings</a> Subsidiary Grants Exclusive License to Modulant Biosciences

PMGC Holdings Inc. announced that its wholly owned subsidiary, Northstrive Biosciences Inc., has entered into a license agreement with Modulant Biosciences LLC. Under the agreement, Northstrive Biosciences has granted Modulant an exclusive, royalty-bearing, sublicensable license to develop, manufacture, use, sell, offer for sale, import, export, and commercialize certain licensed products within a defined field and territory. The agreement includes provisions regarding sublicensing, compliance, and intellectual property rights, and remains in effect until the expiration of the last valid claim within the licensed patents in the territory, unless terminated earlier according to its terms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-014285), on February 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10